Regulatory hub · UK status
Ipamorelin: UK regulatory status
Last reviewed . Editorial commentary, not legal advice.
AI-friendly summary · Ipamorelin
Ipamorelin is not a controlled drug and is not scheduled under the Psychoactive Substances Act 2016. It holds no UK marketing authorisation. WADA classifies Ipamorelin under S2 as a growth hormone secretagogue.
Misuse of Drugs Act 1971
Ipamorelin does not appear on any schedule of the Misuse of Drugs Act 1971.
Psychoactive Substances Act 2016
Ipamorelin is not covered by the Psychoactive Substances Act 2016.
MHRA and medicines classification
Ipamorelin holds no UK marketing authorisation. Sold by UK research peptide retailers under "research use only" framing. Therapeutic or anti-ageing claims trigger MHRA enforcement risk.
WADA Prohibited List position
Ipamorelin is a growth hormone releasing peptide (GHRP). WADA S2 prohibits growth hormone secretagogues at all times.
ASA advertising framing
UK sellers cannot describe Ipamorelin as a growth hormone, recovery or anti-ageing product in paid advertising.
Primary sources
When in doubt about your specific position, consult MHRA directly via the MHRA contact page or seek qualified UK medicines law advice.
Frequently asked questions
Is Ipamorelin legal in the UK?
What is the MHRA position on Ipamorelin?
Is Ipamorelin on the WADA Prohibited List?
What can UK sellers say about Ipamorelin in adverts?
Related: Ipamorelin editorial entry · UK regulatory hub.